慢阻肺临床路径对患者、专业人员及系统结局影响的系统评价
本系统评价纳入13项研究,评估慢阻肺临床路径对患者、专业人员及系统层面结局的影响。结果显示临床路径可显著降低并发症、再入院率和住院时间,但未改变死亡率和生活质量,证据质量普遍较低,需谨慎解读。
要点
- 慢阻肺临床路径可能降低并发症、再入院率和住院时间。
- 临床路径对死亡率和生活质量未见显著影响。
- 总体证据质量较低,结果需谨慎解读。
核心结论
- 慢阻肺临床路径有潜力降低并发症、再入院率和住院时间,且不增加死亡率或降低生活质量。
- 但证据质量普遍较低,结果需谨慎解读,需进一步研究。
研究设计与样本
- 采用Cochrane协作网方法进行系统评价。
- 检索到497条可能相关标题,最终纳入13项研究。
- 纳入研究需符合临床路径操作定义且聚焦慢阻肺。
- 对所有研究进行偏倚风险评估,并提取患者、专业人员和系统结局数据。
主要发现
- 纳入研究共报告398项结局。
- 对并发症、住院时间、死亡率、再入院和生活质量五项结局进行了荟萃分析。
- 结果显示并发症、再入院和住院时间有统计学显著降低。
- 死亡率和生活质量未见显著变化。
临床怎么用
- 临床可考虑实施慢阻肺临床路径以缩短住院时间、减少再入院和并发症。
- 实施时需注意当前证据质量较低,应结合本地情况谨慎决策。
局限性
- 纳入研究的总体证据质量普遍较低。
- 作者指出结果应谨慎解读,并需要更多研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COPD has a substantial burden seen in both patient quality of life and health-care costs. One method of minimizing this burden is the implementation of clinical pathways (CPWs). CPWs bring the best available evidence to a range of health-care professionals by adapting guidelines to a local context and detailing essential steps in care. METHODS: A systematic review was conducted to address the following question: What are the effects of CPWs for COPD on patient-, professional-, and systems-level outcomes? The review used methods outlined by the Cochrane Collaboration. We included all studies that met our operational definition for CPWs and focused on COPD. All studies were evaluated for risk of bias, and all data regarding patient, professional, and systems outcomes were extracted. RESULTS: The search strategy identified 497 potentially relevant titles. Of these, 13 studies were included in the review. These studies reported a total of 398 outcomes, with sufficient data for meta-analysis of five outcomes: complications, length of stay, mortality, readmissions, and quality of life. Results showed statistically significant reductions in complications, readmissions, and length of stay but did not show changes in mortality or quality of life. CONCLUSIONS: This systematic review reveals evidence to suggest that CPWs for COPD have the potential to reduce complications, readmissions, and length of stay without negatively influencing mortality or quality of life. However, quality of evidence was generally low. The authors therefore acknowledge that results should be interpreted with caution and note the need for additional research in this area.
引用
- Plishka CT, Rotter T, Penz ED, et al. Effects of Clinical Pathways for COPD on Patient, Professional, and Systems Outcomes: A Systematic Review. Chest. 2019. PMID: 31150639. doi:10.1016/j.chest.2019.04.131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。